The FDA has approved Abbott Laboratories' AVEIR dual chamber leadless pacemaker system, the world's first of its kind to treat abnormal or slow heart rhythms. The system uses Abbott's proprietary i2i communication technology to provide synchronized cardiac pacing. The approval follows recent clinical data showing that the AVEIR DR system met its safety and efficacy endpoints. ABT shares are down 0.06% at $107.15.